-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35

Benzinga·08/21/2026 15:11:59
Listen to the news
Barclays analyst Glen Santangelo maintains Hims & Hers Health (NYSE:HIMS) with a Overweight and lowers the price target from $39 to $35.